Clinical Trial Flexibility and Customization Needs that are Required by Biotechs and Next Generation Therapies
Brought to you by DIA in cooperation with
COVID-19 has ushered in new challenges when conducting clinical trials, but mid-tier biotech companies have different needs then large pharmaceutical companies. When companies are conducting studies for therapeutic areas such as oncology, or are conducting clinical trials for next generation therapies, a smaller sponsor requires a partner that is nimble, fast acting and flexible, as well as transparent. Communicating what is required is vital, but even more important, having a partner that can communicate what is possible is key. This webinar will outline the 3 areas that mid-tier biotech companies need from CROs, which are people, process and technology.
A Sponsor’s perspective on the decision making criteria for selecting a CRO partners
Need for a niche CRO solution, based on the growth and increased complexities of oncology studies
Technology investments and capabilities that allow CROs to adapt to meet the unique needs of biotechs
Upon completion of the webinar, participants will have a better understanding of:
- Understand the unique needs of small and midsize biotech companies when conducting oncology studies
- Recognize the need for an adaptive and responsive CRO amidst the current landscape and increased demand within the growing biotechnology industry
- Learn CRO best practices for adapting to the specific needs of small and midsize biotechs
- Tailor operational and technological approaches to planning, launching and conducting studies for a growing market
Continuing Education Credits are not available for this event.